INKT · MiNK Therapeutics Inc
United States · RS rating 39 · As of 2026-11-03
| Price | 10.79 USD |
|---|---|
| 1-day change | -2.3% |
| RS rating (overall / 1M / 3M / 12M) | 39 / 33 / 50 / 35 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 27 / 21 / 33 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -8.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +24.1% |
| Market cap (USD) | $53.3M |